11.28SEK+0.18%Mkt Cap: 3.23B SEKP/E: —Last update: 2026-05-13
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-5.98
PEG—
P/B2.95
P/S846.72
EV/EBITDA-3.90
EV/Revenue461.39
EPS (TTM)-1.90
EPS (Forward)-1.92
Cash Flow & Leverage
FCF Yield-6.88%
FCF Margin-5827.45%
Operating CF-375.74M SEK
CapEx (TTM)—
Net Debt/EBITDA2.58
Net Debt-1.17B SEK
Technical
SMA 5010.18 (+10.8%)
SMA 20010.81 (+4.3%)
Beta0.14
S&P 52W Chg24.23%
Avg Vol (30d)495.19K
Avg Vol (10d)592.64K
Technical Indicators
RSI (14)64.4
MACD0.2523
MACD Signal0.1094
MACD Hist.+0.1429
BB Upper11.35 SEK
BB Middle10.40 SEK
BB Lower9.450 SEK
BB Width18.28%
ATR (14)0.4874 SEK
Vol Ratio (20d)0.45x
52W Range
7.35058% of range14.10
52W High14.10 SEK
52W Low7.350 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-12509.14%
Oper. Margin-32143.68%
ROE-43.59%
ROA-39.18%
Revenue Growth-91.80%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio10.28
Quick Ratio9.99
Book Value/Sh3.891 SEK
Cash/Share4.144 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.281.53M
Float198.62M
Insiders12.73%
Institutions55.48%
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)29.50 SEK
Target Range15.00 SEK – 40.00 SEK
# Analysts6
Company
Market Cap3.23B SEK
Enterprise Value1.76B SEK
Revenue (TTM)3.82M SEK
Gross Profit3.82M SEK
Net Income (TTM)-477.47M SEK
Revenue/Share0.0160 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees37
Last Price11.28 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—